StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) shareholders

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.18+0.00 (+2.11%)

Close on Nov 16, 2026Market cap $8.18MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
26.5%
12M of 44M shares
Institutional holders
49
10 new, 16 sold out
Net institutional buying
-4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Michael Kramarz
Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more
4,383,5089.90%13G (passive) amendmentDec 31, 2025
Commodore Capital LP
Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more
4,244,5909.90%13G (passive) amendmentJun 30, 2026
Bvf Partners L P/Il
Joint filing with Bvf Inc/Il (9.97%), Lampert Mark N (9.97%) and 3 more
3,084,3249.97%13G (passive) amendmentDec 31, 2024
Chen Yu
Joint filing with TCG Crossover GP II, LLC (5.10%), TCG Crossover Fund II, L.P. (5.10%)
2,960,4046.70%13G (passive) amendmentJun 30, 2026
Great Point Partners, LLC
Joint filing with Dr. Jeffrey R. Jay, M.D. (6.59%), Ms. Lillian Nordahl (6.59%)
2,055,8346.59%13G (passive) amendmentJun 30, 2025
Ms. Lillian Nordahl
Joint filing with Great Point Partners, LLC (6.28%), Dr. Jeffrey R. Jay, M.D. (6.28%)
2,055,8346.28%13G (passive) amendmentSep 30, 2025
Stempoint Capital LP
Joint filing with Stempoint Capital Management Gp LLC (6.50%), Michelle Ross (6.50%)
1,790,1826.50%13G (passive)Dec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of VTGNValueChange% of portfolio
Commodore Capital LP2,788,6206.28%$630.23KNew0.04%
Vanguard Capital Management LLC1,574,2003.55%$355.77K–0.00%
Two Sigma Investments, LP847,9921.91%$191.65K+378,3730.00%
Acadian Asset Management LLC794,5791.79%$178.00K+204,9160.00%
Renaissance Technologies LLC730,5001.65%$165.09K+439,2000.00%
Stempoint Capital LP616,7491.39%$17.28K−616,7490.00%
Ikarian Capital, LLC519,0771.17%$117.31K–0.01%
AdvisorShares Investments LLC438,6430.99%$99.13K+161,5330.01%
Luminus Management LLC403,1150.91%$91.10K+7,0620.06%
Geode Capital Management, LLC365,0020.82%$82.51K−88,3890.00%
ADAR1 Capital Management, LLC351,1410.79%$79.36K−400,0000.00%
BlackRock, Inc.345,4320.78%$78.07K−103,0750.00%
Group One Trading, L.P.304,3850.69%$68.79K+284,5100.00%
Verdad Advisers, LP293,3430.66%$66.30K+108,4050.06%
Vanguard Fiduciary Trust Co217,7000.49%$49.20K–0.00%
Jane Street Group, LLC164,8270.37%$37.25K−107,9840.00%
Boothbay Fund Management, LLC134,5710.30%$30.41K–0.00%
State Street Corp121,1140.27%$27.37K–0.00%
XTX Topco Ltd118,3800.27%$26.75K−34,4690.00%
Northern Trust Corp80,8230.18%$18.27K+8,1680.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20264912M26.5%10 / 1514 / 165M8M
Q1 20265615M34.6%16 / 159 / 145M1M
Q4 20255514M31.0%14 / 1815 / 163M13M
Q3 20255824M53.9%14 / 1910 / 710M1M
Q2 20255115M34.9%6 / 1712 / 30M1M
Q1 20254816M35.9%3 / 1220 / 91M1M
Q4 20245416M35.0%15 / 1910 / 84M3M
Q3 20244715M34.4%9 / 914 / 34M3M
Q2 20244215M34.2%7 / 814 / 62M1M
Q1 20244115M33.0%7 / 1210 / 111M3M
Q4 20234517M37.7%23 / 162 / 1214M1M
Q3 2023343M6.8%13 / 117 / 112M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

18 funds held VTGN in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of VTGNValue% of fundAs of
Vanguard Total Stock Market Index Fund1,160,4552.61%$262.26K0.00%Jun 30, 2026
AdvisorShares Psychedelics ETF438,6430.99%$99.13K0.22%Jun 30, 2026
Vanguard Extended Market Index Fund413,7450.93%$93.51K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund266,1410.60%$167.67K0.00%May 31, 2026
Fidelity Series Total Market Index Fund48,9030.11%$30.81K0.00%May 31, 2026
Fidelity Total Market Index Fund46,9610.11%$29.59K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund12,1890.03%$7.68K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund4,9470.01%$1.12K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Shawn SinghPresident and CEO, Director75,7210.17%Jul 2, 2026
Nick B. TresslerChief Financial Officer11,7120.03%Jul 2, 2026
Reid G. AdlerChief Legal Officer60,8680.14%Jul 2, 2026
Angel S. AngelovChief Medical Officer––May 19, 2026
Joshua S. PrinceChief Operating Officer15,2490.03%Apr 9, 2026
Elissa S. CoteChief Corp Development Officer––Apr 9, 2026
Cynthia Lynn AndersonCHIEF FINANCIAL OFFICER12,8010.03%Jul 1, 2025
Douglas J. WilliamsonDirector––Jul 31, 2026
Paul R. EdickDirector––Nov 4, 2025
Joanne CurleyDirector––Sep 11, 2025
Mary L. RotunnoDirector––Sep 11, 2025
Ann Michelle CunninghamDirector––Sep 11, 2025
Jon S. SaxeDirector55,7510.13%Sep 11, 2025
Margaret M. FitzPatrickDirector––Sep 11, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Reid G. Adler
Chief Legal Officer
Jun 30, 2026Award+36,818$0.19$7.00K60,868
Nick B. Tressler
Chief Financial Officer
Jun 30, 2026Award+11,712$0.19$2.23K11,712
Shawn Singh
President and CEO, Director
Jun 30, 2026Award+36,818$0.19$7.00K54,846
Joshua S. Prince
Chief Operating Officer
Dec 31, 2025Award+4,386$0.56$2.46K15,249
Shawn Singh
President and CEO, Director
Jun 30, 2025Award+7,541$1.70$12.82K18,028
Reid G. Adler
Chief Legal Officer
Jun 30, 2025Award+7,541$1.70$12.82K24,050
Joshua S. Prince
Chief Operating Officer
Jun 30, 2025Award+4,882$1.70$8.30K10,863
Cynthia Lynn Anderson
CHIEF FINANCIAL OFFICER
Jun 30, 2025Award+6,617$1.70$11.25K12,801
Cynthia Lynn Anderson
CHIEF FINANCIAL OFFICER
Dec 31, 2024Award+2,592$2.51$6.51K6,184
Joshua S. Prince
Chief Operating Officer
Dec 31, 2024Award+3,310$2.51$8.31K5,981
Reid G. Adler
CHF CORP DEVEL OFF, GEN COUNS
Jun 28, 2024Award+4,854$2.96$14.37K16,509
Joshua S. Prince
Chief Operating Officer
Jun 28, 2024Award+2,671$2.96$7.91K2,671
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Jun 28, 2024Award+4,854$2.96$14.37K10,487
Cynthia Lynn Anderson
CHIEF FINANCIAL OFFICER
Jun 28, 2024Award+3,592$2.96$10.63K3,592
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Dec 29, 2023Award+167$1.72$2875,633
Reid G. Adler
CHF CORP DEVEL OFF, GEN COUNS
Dec 29, 2023Award+167$1.72$28711,655
Capital Lp Commodore
10% owner
Aug 7, 2023Buy+775,756$23.15$17.96M1,575,000
Jerrold Duane Dotson
VP, CFO
Jun 30, 2023Award+167$1.59$2663,671
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Jun 30, 2023Award+167$1.59$2665,466
Reid G. Adler
CHIEF LEGAL OFFICER
Jun 30, 2023Award+167$1.59$26611,488
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Dec 30, 2022Award+5,000$0.09$450105,111
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Dec 30, 2022Award+5,000$0.09$450158,998
Jerry B. Gin
Director
Aug 18, 2022Buy+100,000$0.18$18.00K100,000
Jerry B. Gin
Director
Aug 18, 2022Buy+100,000$0.18$18.00K100,000
Reid G. Adler
CHIEF LEGAL OFFICER
Aug 17, 2022Buy+300,000$0.17$51.00K334,629
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Aug 17, 2022Buy+600,000$0.17$102.00K626,234
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jul 30, 2022Award+5,000$0.75$3.75K100,111
VHCP Management II, LLC
10% owner
Jul 12, 2022Sale−60,000$0.89$53.40K20,637,286
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Jun 30, 2022Award+5,000$0.75$3.75K153,998
Mark Alan Smith
CHIEF MEDICAL OFFICER
Jun 30, 2022Award+5,000$0.75$3.75K19,915
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
May 12, 2022Option exercise+100,000$1.00$100.00K148,998
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jan 11, 2022Option exercise+18,750$1.00$18.75K94,571
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Dec 31, 2021Award+3,623$1.66$6.01K48,998
Mark Alan Smith
CHIEF MEDICAL OFFICER
Dec 31, 2021Award+2,655$1.66$4.41K14,915
1415876
PRES./CHIEF SCIENTIFIC OFFICER
Dec 31, 2021Award+3,623$1.66$6.01K64,958
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Dec 31, 2021Award+3,575$1.66$5.93K75,821
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Sep 7, 2021Sale−30,000$3.13$93.90K72,786
1415876
PRES./CHIEF SCIENTIFIC OFFICER
Sep 2, 2021Gift+1,111––61,335
1415876
PRES./CHIEF SCIENTIFIC OFFICER
Aug 23, 2021Gift−740––33,901
1415876
PRES./CHIEF SCIENTIFIC OFFICER
Aug 17, 2021Buy+3,750$2.73$10.24K34,641
Mark Alan Smith
CHIEF MEDICAL OFFICER
Jun 30, 2021Award+2,260$1.95$4.41K12,260
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jun 30, 2021Award+3,044$1.95$5.94K13,044
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jun 30, 2021Option exercise+1,000$1.50$1.50K14,044
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jun 30, 2021Option exercise+78,918$1.00$78.92K92,962
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jun 30, 2021Option exercise+9,824$0.40$3.93K102,786
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Jun 30, 2021Award+5,000$1.95$9.75K45,375
1415876
PRES./CHIEF SCIENTIFIC OFFICER
Jun 30, 2021Award+3,391$1.95$6.61K91,115
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Apr 23, 2021Option exercise+5,000$1.50$7.50K40,375
Jon S. Saxe
Director
Mar 19, 2021Option exercise+2,500$1.50$3.75K5,751
Brian J. Underdown
Director
Mar 19, 2021Option exercise+2,500$1.50$3.75K2,500
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Dec 31, 2020Award+5,000$0.45$2.25K35,375
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Dec 31, 2020Award+5,000$0.45$2.25K10,000
1415876
PRES./CHIEF SCIENTIFIC OFFICER, Director
Dec 31, 2020Award+5,000$0.45$2.25K87,724
Mark Alan Smith
CHIEF MEDICAL OFFICER
Dec 31, 2020Award+5,000$0.45$2.25K10,000
Jon S. Saxe
Director
Aug 21, 2020Buy+30,000$0.69$20.70K50,000
1415876
PRES./CHIEF SCIENTIFIC OFFICER, Director
Jun 30, 2020Award+5,000$0.45$2.25K67,724
Shawn Singh
CHIEF EXECUTIVE OFFICER, Director
Jun 30, 2020Award+5,000$0.45$2.25K30,375
Mark Alan Smith
CHIEF MEDICAL OFFICER
Jun 30, 2020Award+5,000$0.45$2.25K5,000
Jerrold Duane Dotson
VP, CFO AND SECRETARY
Jun 30, 2020Award+5,000$0.45$2.25K5,000
1415876
PRES./CHIEF SCIENTIFIC OFFICER, Director
Nov 20, 2019Buy+15,000$0.34$5.10K15,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
5.64%
2M shares short
Days to cover
3.4
At 1M shares a day
Change since last report
+0.6%
From 2M shares
Short volume, 20 days
52.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vistagen Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,641,884 shares on Sep 24, 2026 over the last 90 days.

See a number that looks wrong?